Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Subjects 18 years or older having received IXIARO batch JEV09L37 during primary immunization

In female subjects, either childbearing potential terminated by surgery or 1 year post-menopausal, or a negative urine pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception

Written informed consent obtained from the subject prior to any study-related procedures

Exclusion Criteria:

Vaccination against Yellow fever, Dengue Fever, West Nile Fever or TBE or vaccination with any JE vaccine since primary immunization with IXIARO JEC09L37

Clinical manifestation of any flavivirus infection since primary immunization with IXIARO JEC09L37

Acute febrile infections or exacerbation of chronic infection on the day of IXIARO vaccination